ONO Signs a Research Collaboration with Repare Therapeutics for its Polθ Inhibitor Program

 ONO Signs a Research Collaboration with Repare Therapeutics for its Polθ Inhibitor Program

ONO Signs a Research Collaboration with Repare Therapeutics for its Polθ Inhibitor Program

Shots:

  • Repare to receive $15M upfront, $160M milestones and royalties on sales of product from ONO. Repare to get exclusive development and commercialization rights for Repare’s Polθ Inhibitor Program in Japan, South Korea, Taiwan, Hong Kong, Macau and ASEAN countries
  • Repare will retain development and commercialization rights (ex- ONO’s territory) for Polθ Inhibitor Program in the US, Canada and EU
  • Polθ inhibitor is a DNA Polymerase θ targeted to repair DNA breaks in homologous recombination deficient (HRD) cells and has ability to play vital role in breast and ovarian cancer including prostate and pancreatic in combination with chemotherapy, radiotherapy and Immuno-Oncology agent

Click here to read full press release/ article | Ref: Repare Therapeutics | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post